[HTML][HTML] Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data
Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is
a 5-HT 3, 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT …
a 5-HT 3, 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT …
Major depression: one brain, one disease, one set of intertwined processes
EV Filatova, MI Shadrina, PA Slominsky - Cells, 2021 - mdpi.com
Major depressive disorder (MDD) is a heterogeneous disease affecting one out of five
individuals and is the leading cause of disability worldwide. Presently, MDD is considered a …
individuals and is the leading cause of disability worldwide. Presently, MDD is considered a …
A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
RS McIntyre, S Lophaven… - International Journal of …, 2014 - academic.oup.com
The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression
in adults with recurrent moderate-to-severe major depressive disorder (MDD) was …
in adults with recurrent moderate-to-severe major depressive disorder (MDD) was …
A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder
AR Mahableshwarkar, J Zajecka, W Jacobson… - …, 2015 - nature.com
This multicenter, randomized, double-blind, placebo-controlled, active-referenced
(duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of …
(duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of …
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
TH Pham, AM Gardier - Pharmacology & therapeutics, 2019 - Elsevier
Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
Cognitive remission: a novel objective for the treatment of major depression?
Background Cognitive dysfunction in major depressive disorder (MDD) encompasses
several domains, including but not limited to executive function, verbal memory, and …
several domains, including but not limited to executive function, verbal memory, and …
Vortioxetine: clinical pharmacokinetics and drug interactions
G Chen, AM Højer, J Areberg, G Nomikos - Clinical pharmacokinetics, 2018 - Springer
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the
treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5-to …
treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5-to …
Integrating the monoamine, neurotrophin and cytokine hypotheses of depression—a central role for the serotonin transporter?
Monoamine, in particular serotonergic neurotransmission has long been recognized as an
important factor in the aetiology of depression. The serotonin transporter (SERT) is the …
important factor in the aetiology of depression. The serotonin transporter (SERT) is the …
Prefrontal cortex executive processes affected by stress in health and disease
M Girotti, SM Adler, SE Bulin, EA Fucich… - Progress in Neuro …, 2018 - Elsevier
Prefrontal cortical executive functions comprise a number of cognitive capabilities necessary
for goal directed behavior and adaptation to a changing environment. Executive dysfunction …
for goal directed behavior and adaptation to a changing environment. Executive dysfunction …
Depression and cognition in the elderly
S Wang, DG Blazer - Annual review of clinical psychology, 2015 - annualreviews.org
This review provides an overview of the relationship between depression and cognition in
the elderly, with an emphasis on psychotherapies and nonpharmacologic approaches. We …
the elderly, with an emphasis on psychotherapies and nonpharmacologic approaches. We …